News Desk
As genomic tools sharpen, Indian scientists advance rare disease research while national programs target chronic conditions. Experts say it’s only the beginning.
NEW DELHI — In quiet laboratories across the country, Indian scientists are rewriting the story of complex diseases. From decoding rare genetic mutations to mapping the spread of chronic conditions, India’s medical research community is increasingly shaping global understanding — and bolstering domestic health care in the process.
Backed by national policy, powerful genomic technologies, and an emerging ecosystem of specialized institutions, India is making substantial headway in diagnosing diseases long considered elusive. Rare diseases, once consigned to the periphery of public health discourse, are finally receiving sustained scientific attention.
In a landmark study spanning two decades, researchers found that diagnostic yields from clinical and whole exome sequencing — the workhorse technologies of genomic medicine — have risen from 30 percent in 2000 to more than 49 percent in 2022. This leap is not merely technological; it represents a paradigm shift in how the country detects and understands rare diseases.
At the heart of this transformation is the Indian Council of Medical Research’s National Registry for Rare Diseases, which has cataloged more than 4,000 rare conditions. Backed by a network of 35 major research institutions, Indian scientists are publishing high-impact studies on disorders ranging from lysosomal storage diseases to skeletal dysplasias. For instance, a 2023 study identified a probable Gujarati-Indian founder mutation linked to Mucopolysaccharidosis IVA — a breakthrough that could streamline targeted screening in affected communities.
These efforts are more than academic. India has begun developing cost-effective diagnostic platforms suited to its scale and constraints. A 2024 study validated a single-molecule inversion probe technology for screening 29 lysosomal storage disorders — a tool with the potential to make advanced diagnostics accessible across rural and underserved areas.
India’s growing contribution to global biomedical literature is also being felt in citation indices. Publications originating from Indian institutions — once overlooked in international discussions on rare diseases — are increasingly referenced in top-tier journals. For example, research on Mucolipidosis Types II and III published in Journal of Human Genetics in 2020 identified 30 novel mutations in Indian patients, underscoring the country’s rich and unique genomic diversity.
India’s scientific momentum is also visible in the fight against chronic noncommunicable diseases (NCDs), which account for nearly 60 percent of all deaths in the country. The National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases, and Stroke (NPCDCS) represents a coordinated effort to tackle this burden through early diagnosis and integrated care.
Yet challenges persist. Public health spending on NCDs remains modest — less than 0.5 percent of the National Health Mission’s total outlay in 2017–18 — and primary health centers face infrastructure and personnel gaps. However, state-level innovations are beginning to show promise. Tamil Nadu, for instance, has piloted decentralized NCD clinics and mobile health units, reaching remote populations with regular screening for diabetes and hypertension. Chronic Diseases in India—Ubiquitous Across the Socioeconomic Spectrum” (JAMA Network Open, 2019)
Meanwhile, research on chronic diseases is offering valuable epidemiological insights. Between 1990 and 2016, disability-adjusted life years (DALYs) due to diabetes in India rose by 170 percent, prompting calls for preventive action. Studies also highlight how obesity and NCD risk factors are rising even among women with little or no education — a sign that lifestyle diseases are no longer urban afflictions alone.
India’s approach combines ambition with pragmatism. The country is unlikely to outspend high-income nations on health, but it is increasingly out-innovating them in creating scalable, cost-sensitive solutions. It is here that the Indian research model stands out — marrying molecular diagnostics with public health frameworks to create a unique pathway to progress.
That model is gaining international attention. Researchers from India have collaborated on global projects to standardize newborn screening protocols and improve diagnosis for conditions such as congenital adrenal hyperplasia and Gaucher disease. And Indian-led studies continue to unlock new understandings: a 2023 paper on autism spectrum disorders proposed WES as a first-tier diagnostic approach — findings that are now influencing guidelines beyond India’s borders.
India’s growing use of Whole Exome Sequencing (WES) is reshaping the landscape of rare disease diagnostics, offering new hope for millions with elusive conditions. Unlike whole genome sequencing, WES focuses on just 1 to 2 percent of the genome — the exome — where more than 85 percent of disease-causing mutations are known to reside. That narrow lens is proving to be a powerful tool, especially in a country as genetically diverse as India.
Over the past two decades, diagnostic yields from WES have steadily climbed, from just 30 percent in the early 2000s to over 49 percent in 2022. In clinical settings, it has become particularly useful for diagnosing neuromuscular and neurodevelopmental disorders, lysosomal storage diseases, and inborn errors of metabolism — conditions that often leave families in diagnostic limbo for years.
Indian research centers have embraced WES not only for its precision but also for its cost-effectiveness. In many cases, it eliminates the need for a battery of inconclusive tests, streamlining diagnosis and cutting costs. In recent years, scientists have identified more than 30 novel disease-causing mutations in Indian patients, including founder mutations unique to specific communities — such as the GALNS p.P77R variant linked to Mucopolysaccharidosis IVA among Gujaratis.
WES is now being proposed as a first-line diagnostic tool in India’s major tertiary care hospitals and research institutions. And looking ahead, experts are calling for its integration into newborn screening programs and expanded carrier testing, especially in communities with a high burden of inherited disorders. The promise of WES in India is not just about cutting-edge science — it’s about accessibility, equity, and rewriting the future of families long burdened by diagnostic uncertainty.
In hospital wards and consultation rooms across Tamil Nadu, some families have learned the hard way that a simple diagnosis of “developmental delay” can sometimes mask something far more complex — and far more rare.
Take the case of Mithraa, a child from Namakkal, whose struggle with walking and lifting objects was initially attributed to a generic bone issue. It wasn’t until further genetic testing in 2021 that doctors discovered she had Spinal Muscular Atrophy (SMA) Type 2, a rare neuromuscular disorder that gradually weakens the body’s motor functions. The diagnosis unlocked access to specialized treatments — but it also brought the daunting challenge of funding therapies that can cost crores of rupees. (The New Indian Express, The News Minute, The Times of India)
More recently, in 2024, Krithikraj, a one-and-a-half-year-old boy from Cuddalore district, was diagnosed with the same condition after showing symptoms as early as eight months old. His family, like so many others, now faces the uphill task of gathering public and governmental support for the ₹16-crore medication that could change his life. (The New Indian Express)
While there may not be a widely reported case from Chennai matching this pattern exactly, the trend is undeniable: children across Tamil Nadu with rare genetic disorders are too often caught in a cycle of misdiagnosis and delay. Their stories underscore a critical truth — timely and precise genetic testing doesn’t just clarify what’s wrong; it can radically shift what’s possible.
The road is not without obstacles. Treatment breakthroughs have lagged behind diagnostic advances, especially for rare diseases where therapies remain prohibitively expensive. In chronic disease management, frontline infrastructure remains patchy, and essential medicines are often in short supply. Yet India’s trajectory — from laggard to leader in certain research domains — is unmistakable.
Future steps include proposals for nationwide newborn screening programs, expanded use of genomic panels, and integration of AI tools to assist rural clinicians. With the world’s largest youth population and a swelling middle class demanding quality care, India’s health innovation ecosystem is poised to grow.
As the country races to meet the twin challenges of complexity and scale, its scientists are ensuring that India not only catches up — but helps lead the way.
Across laboratories and clinics from Ahmedabad to Hyderabad, Indian scientists are building a genetic atlas of some of the world’s rarest and most complex diseases. In recent years, a string of studies has helped decode the unique genetic makeup of India’s population — a breakthrough for both global research and local diagnostics.
In 2023, researchers studying Mucopolysaccharidosis IVA, a debilitating lysosomal storage disorder, identified a probable founder mutation — the GALNS p.P77R variant — common in Gujarat. The discovery has opened the door to community-specific screening in the region, setting a precedent for more tailored diagnostic approaches.
Two years earlier, in 2022, scientists validated a next-generation sequencing (NGS) assay for Congenital Adrenal Hyperplasia in over 300 Indian cases, providing a reliable diagnostic route for a condition that often goes unrecognized in newborns.
Back in 2020, Indian geneticists broke ground by identifying 30 previously unknown mutations in patients with Mucolipidosis Types II and III, helping global researchers better understand the disease’s variability and severity across ethnic groups.
Even in earlier years, the momentum was clear. A 2018 study offered the most comprehensive mapping of the mutation spectrum for GNE Myopathy in the Indian subcontinent — a muscle-wasting disease that disproportionately affects South Asian populations. And as far back as 2015, clinicians were already ringing alarm bells over the challenges of early diagnosis for lysosomal storage disorders, calling for better infrastructure and greater awareness in India’s public health system.
Together, these research milestones tell a larger story — not just of discovery, but of determination. In a country long burdened by underdiagnosis, India’s scientists are quietly changing the narrative, gene by gene.
This article is based on a review of published academic research, government policy documents, and verified media reports. Case studies were drawn from reputable Indian news outlets including The New Indian Express, The News Minute, and The Times of India. Research highlights were synthesized from peer-reviewed journals and official updates from institutions such as the Indian Council of Medical Research. Our focus is only policy and communication.
